AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01574638
Drug: Rifapentine (RPT)
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.
Trial: NCT01495884
Drug: Lapatinib (Tyverb™)
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00058422
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00058422
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01450748
Drug: Sodium alginate
RxNorm normalized name: Sodium Alginate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
Trial: NCT00330915
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m2, intravenous (IV), every 21 days x 3 cycles
Trial: NCT00519701
Drug: hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02504125
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
Trial: NCT04116827
Drug: Tamoxifen Oral Tablet
RxNorm normalized name: tamoxifen Oral Tablet
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who are scheduled for application of tamoxifen and goserelin
Trial: NCT04496999
Drug: Midostaurin
RxNorm normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Midostaurin 50mg bid d1-28 (morning, evening)
Trial: NCT03589976
Drug: Sirolimus 2 MG
RxNorm normalized name: sirolimus 2 MG
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose will be adjusted throughout this trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose will be 6mg/day.
Trial: NCT02613039
Drug: Combined Estrogen-Progestin Oral Contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients enrolled will undergo Combined Estrogen-Progestin Oral Contraceptives. Different compounds will be chosen according to the approved indications and clinical practice. Therefore it is not possible to provide a specific trade and/or generic name.
Trial: NCT03671109
Drug: Dihydroartemisinin-piperaquine (DHA-PPQ)
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-DHA-PPQ under supervision
Trial: NCT00771251
Drug: CNTO 148
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.
Trial: NCT01296542
Drug: Moxifloxacin Ophthalmic
RxNorm normalized name: Moxifloxacin Ophthalmic
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01296542
Drug: Besifloxacin Ophthalmic
RxNorm normalized name: besifloxacin ophthalmic
DrugBank: Besifloxacin (DB06771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04336748
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low dose (200mg) Hydroxychloroquine once daily for 4 weeks
Trial: NCT00196339
Drug: Cyproterone acetate 5
RxNorm normalized name: Cyproterone acetate 50 mg oral tablet
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 5 mg
Trial: NCT00196339
Drug: Cyproterone acetate 15
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 15 mg
Trial: NCT00196339
Drug: Cyproterone acetate 25
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 25 mg
Trial: NCT01714843
Drug: linaclotide
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT02210247
Drug: EXPAREL
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03875092
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT03875092
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion Carboplatin dose should not exceed 900 mg.
Trial: NCT03875092
Drug: Saline placebo for pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT02573025
Drug: PEG-IFN alfa-2a BA-free formulation (Test)
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
Trial: NCT03205761
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
Trial: NCT01088880
Drug: Canakinumab
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02375880
Drug: DKN-01
RxNorm normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous (IV) infusion.
Trial: NCT02375880
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by IV infusion.
Trial: NCT02375880
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion
Trial: NCT04420585
Drug: Desmopressin
RxNorm normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
Trial: NCT02573025
Drug: PEG-IFN alfa-2a market formulation (Reference)
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
Trial: NCT02307201
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patient will receive magnesium sulfate for 24 hours postpartum
Trial: NCT02066818
Drug: Lidocaine/tetracaine patch
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02066818
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02715700
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methadone 20 to 200 mg (10 mg/mL if oral solution concentrate) oral tablet once per day.
Trial: NCT04540926
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 pneumonia patients treated with oral CsA at a dose of 1-2 mg /kg / day divided into two doses, for 7 days, since entering to hospitalization.
Trial: NCT01868555
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Trial: NCT01201811
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
Trial: NCT02715700
Drug: Doravirine
RxNorm normalized name: Doravirine
DrugBank: Doravirine (DB12301)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Doravirine 100 mg oral tablet once per day.
Trial: NCT00977756
Drug: Ritonavir (RTV)
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg daily, dosing by weight in Group I
Trial: NCT02263248
Drug: venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.
Trial: NCT01868555
Drug: insulin degludec/insulin aspart 30
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Trial: NCT01868555
Drug: insulin degludec/insulin aspart 45
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Trial: NCT02169609
Drug: Dinutuximab. Immunotherapy
DrugBank: Dinutuximab (DB09077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses.~Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy.
Trial: NCT00549666
Drug: Lurasidone 40 mg
RxNorm normalized name: lurasidone 40 mg oral tablet
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lurasidone 40 mg days 12-21 once daily
Trial: NCT00549666
Drug: Ortho Tri-Cyclen
RxNorm normalized name: Ortho Tri-Cyclen
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ortho Tri-Cyclen during 28-day lead in period
Trial: NCT02263248
Drug: buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd
Trial: NCT00009763
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00009763
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00907933
Drug: SB-705498
RxNorm normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg intranasal SB-705498
Trial: NCT00907933
Drug: SB-705498
RxNorm normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5mg intranasal SB-705498
Trial: NCT00907933
Drug: SB-705498
RxNorm normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg intranasal SB-705498
Trial: NCT00907933
Drug: SB-705498
RxNorm normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg intranasal SB-705498
Trial: NCT00907933
Drug: SB-705498
RxNorm normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12mg intranasal SB-705498
Trial: NCT00907933
Drug: SB-705498
RxNorm normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg intranasal SB-705498 for 14 days bid
Trial: NCT00907933
Drug: SB-705498
RxNorm normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12mg intranasal SB-705498 14 days bid
Trial: NCT02228304
Drug: NT-503-3 ECT implantation
RxNorm normalized name: ECT-001 expanded UCB
DrugBank: CT-001 (DB18284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
Trial: NCT00672386
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.
Trial: NCT00977756
Drug: Tenofovir (TDF)
RxNorm normalized name: emtricitabine/tenofovir (TDF) 200 mg-300 mg ORAL TABLET
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg daily
Trial: NCT00977756
Drug: Etravirine (ETV)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200 mg BID
Trial: NCT00977756
Drug: Darunavir (DRV)
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosing by weight
Trial: NCT00977756
Drug: Maraviroc (MVC)
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg BID in groups J and K; 600 mg BID in group L
Trial: NCT02857426
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02551523
Drug: Dolutegravir
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 92 patients will be simplified to once daily dolutegravir monotherapy
Trial: NCT02123615
Drug: Gadolinium For abdomen
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.~Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
Trial: NCT02123615
Drug: Gadolinium For abdomen
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.~Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs.
Trial: NCT02123615
Drug: Gadolinium For abdomen
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
Trial: NCT00487058
Drug: Gimatecan
RxNorm normalized name: Gimatecan
DrugBank: Gimatecan (DB06721)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03319784
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients assigned to Steroid group will receive 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
Trial: NCT03587142
Drug: Buspirone
RxNorm normalized name: Buspirone
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buspirone tablet
Trial: NCT03306901
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3,200 \~ 4,000mg/m2 intravenously for 4 to 5 days.
Trial: NCT02123615
Drug: Gadolinium For lower back
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.
Trial: NCT02123615
Drug: Gadolinium For lower back
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.
Trial: NCT03306901
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45\~60mg intravenously over 1 hour on day 1
Trial: NCT02707458
Drug: Probucol
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probucol was used with good effect for more than a decade in Canada and the US to reduce plasma cholesterol. Although withdrawn from the Canadian and US markets by its manufacturer for commercial reasons, it is still widely used for this purpose in Japan and Korea. Over the past decade, long-term follow-up studies in Asian populations at high risk of cardiovascular events have shown that the drug reduces the incidence of these events in a manner not unlike statin drugs used widely in Canada and the US.
Trial: NCT02768662
Drug: OTO-104
RxNorm normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intratympanic injection of 12 mg OTO-104
Trial: NCT02123615
Drug: Gadolinium For lower back
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Trial: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
RxNorm normalized name: Gammagard
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.